Save Studies Locally

We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.

By allowing this, you consent to storing study selections locally on your device. Privacy Policy

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)

Description:

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers.

Sponsor:

Lantheus Medical Imaging

Contacts:

Eryn Bagley (Clinical Trial Lead)

eryn.bagley@lantheus.com

Government Study Link:

NCT06298916 - Click here to see study on

ClinicalTrials.gov

64Cu-LNTH-1363S

Isotope(s):

Target(s):

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States 🇺🇸

Cincinnati Children's Hospital Medical Centre

Cincinnati, Ohio 45229, United States

BAMF Health

Grand Rapids, Michigan 49503, United States

Stanford Hospital and Clinics

Stanford, California 94305, United States

University of California Irvine Chao Family Comprehensive Cancer Center

Orange, California, United States

Contact XCancer: 402-991-8468